Trial
NCT05378464
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Vaccinex Inc.
Condition
HER2-positive Breast Cancer
Intervention
Dendritic Cell (DC1) Vaccine
Why stopped
Wait for the DLT period with our current patient and will not be enrolling any more.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-18